Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 88 filers reported holding Y-MABS THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.04 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $15 | -25.0% | 1,217 | 0.0% | 0.00% | – |
| Q1 2024 | $20 | -28.6% | 1,217 | -70.5% | 0.00% | – |
| Q4 2023 | $28 | +16.7% | 4,121 | -8.1% | 0.00% | – |
| Q3 2023 | $24 | -20.0% | 4,483 | 0.0% | 0.00% | – |
| Q2 2023 | $30 | +20.0% | 4,483 | -11.2% | 0.00% | – |
| Q1 2023 | $25 | -10.7% | 5,049 | -13.2% | 0.00% | – |
| Q4 2022 | $28 | -100.0% | 5,819 | 0.0% | 0.00% | -100.0% |
| Q3 2022 | $84,000 | -3.4% | 5,819 | +1.6% | 0.00% | 0.0% |
| Q2 2022 | $87,000 | +27.9% | 5,727 | +0.4% | 0.00% | 0.0% |
| Q1 2022 | $68,000 | -69.5% | 5,706 | -13.5% | 0.00% | -50.0% |
| Q2 2021 | $223,000 | -5.5% | 6,599 | +38.5% | 0.00% | -77.8% |
| Q4 2020 | $236,000 | +14.0% | 4,764 | -0.6% | 0.01% | -10.0% |
| Q2 2020 | $207,000 | – | 4,792 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 191,176 | $2,757,000 | 9.37% |
| Sofinnova Investments, Inc. | 2,194,278 | $31,641,000 | 1.84% |
| MPM BioImpact LLC | 443,702 | $6,398,000 | 1.52% |
| Artal Group S.A. | 400,000 | $5,768,000 | 0.25% |
| Polar Capital Holdings Plc | 2,531,546 | $36,505,000 | 0.23% |
| ASHFORD CAPITAL MANAGEMENT INC | 101,970 | $1,470,000 | 0.22% |
| Lombard Odier Asset Management (Switzerland) SA | 168,795 | $2,434,000 | 0.21% |
| Soleus Capital Management, L.P. | 87,182 | $1,257,000 | 0.17% |
| Cormorant Asset Management, LP | 150,000 | $2,163,000 | 0.15% |
| Walleye Capital LLC | 437,344 | $6,307,000 | 0.12% |